Ingmar Bruns - 08 Jan 2026 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Medical Officer
Signature
/s/ James B. Bucher, attorney-in-fact for Ingmar Bruns
Issuer symbol
ZNTL
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 20:34:52 UTC
Previous filing
12 Feb 2025
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bruns Ingmar Chief Medical Officer C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO /s/ James B. Bucher, attorney-in-fact for Ingmar Bruns 09 Jan 2026 0001838041

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +365,000 $0.000000 365,000 08 Jan 2026 Common Stock 365,000 $2.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney